Klara Dorman

Closest collaborators

The 25 strongest of 48 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Volker Heinemann · 10 shared papers, 2022–2026 · strength 1.72
   • Paper Distinct Mutation Signatures in Peripheral Blood Mitochondrial DNA from Liquid Biopsy Reveal Insights into Pancreatic C… DOI 10.3390/cells15060527↗
   • Paper Novel systemic treatment approaches for metastatic pancreatic cancer. DOI 10.1080/13543784.2022.2037552↗
   • Paper Gemcitabine and nab-paclitaxel combined with afatinib in metastatic pancreatic cancer - Results of a phase 1b clinical … DOI 10.1016/j.ejca.2024.113926↗
2. Stefan Hubert Boeck · 10 shared papers, 2022–2026 · strength 1.72
   • Paper Distinct Mutation Signatures in Peripheral Blood Mitochondrial DNA from Liquid Biopsy Reveal Insights into Pancreatic C… DOI 10.3390/cells15060527↗
   • Paper Novel systemic treatment approaches for metastatic pancreatic cancer. DOI 10.1080/13543784.2022.2037552↗
   • Paper Gemcitabine and nab-paclitaxel combined with afatinib in metastatic pancreatic cancer - Results of a phase 1b clinical … DOI 10.1016/j.ejca.2024.113926↗
3. Michael Haas · 8 shared papers, 2023–2026 · strength 1.35
   • Paper Distinct Mutation Signatures in Peripheral Blood Mitochondrial DNA from Liquid Biopsy Reveal Insights into Pancreatic C… DOI 10.3390/cells15060527↗
   • Paper Gemcitabine and nab-paclitaxel combined with afatinib in metastatic pancreatic cancer - Results of a phase 1b clinical … DOI 10.1016/j.ejca.2024.113926↗
   • Paper Changes over time in the course of advanced pancreatic cancer treatment with systemic chemotherapy: a pooled analysis o… DOI 10.1016/j.esmoop.2024.102944↗
4. Christoph Benedikt Westphalen · 7 shared papers, 2023–2024 · strength 1.10
   • Paper Gemcitabine and nab-paclitaxel combined with afatinib in metastatic pancreatic cancer - Results of a phase 1b clinical … DOI 10.1016/j.ejca.2024.113926↗
   • Paper Changes over time in the course of advanced pancreatic cancer treatment with systemic chemotherapy: a pooled analysis o… DOI 10.1016/j.esmoop.2024.102944↗
   • Paper Three-month life expectancy as inclusion criterion for clinical trials in advanced pancreatic cancer: is it really a va… DOI 10.1007/s12094-023-03323-1↗
5. Lena Weiss · 6 shared papers, 2023–2024 · strength 0.95
   • Paper Gemcitabine and nab-paclitaxel combined with afatinib in metastatic pancreatic cancer - Results of a phase 1b clinical … DOI 10.1016/j.ejca.2024.113926↗
   • Paper Changes over time in the course of advanced pancreatic cancer treatment with systemic chemotherapy: a pooled analysis o… DOI 10.1016/j.esmoop.2024.102944↗
   • Paper Three-month life expectancy as inclusion criterion for clinical trials in advanced pancreatic cancer: is it really a va… DOI 10.1007/s12094-023-03323-1↗
6. Danmei Zhang · 6 shared papers, 2023–2024 · strength 0.92
   • Paper Gemcitabine and nab-paclitaxel combined with afatinib in metastatic pancreatic cancer - Results of a phase 1b clinical … DOI 10.1016/j.ejca.2024.113926↗
   • Paper Three-month life expectancy as inclusion criterion for clinical trials in advanced pancreatic cancer: is it really a va… DOI 10.1007/s12094-023-03323-1↗
   • Paper Clinical Impact of Structured Post-Operative Surveillance in Resected Pancreatic Adenocarcinoma: Results from a Retrosp… DOI 10.1159/000528722↗
7. Anke Reinacher‐Schick · 5 shared papers, 2023–2024 · strength 0.78
   • Paper Changes over time in the course of advanced pancreatic cancer treatment with systemic chemotherapy: a pooled analysis o… DOI 10.1016/j.esmoop.2024.102944↗
   • Paper Three-month life expectancy as inclusion criterion for clinical trials in advanced pancreatic cancer: is it really a va… DOI 10.1007/s12094-023-03323-1↗
   • Paper Alternating gemcitabine plus nab-paclitaxel and gemcitabine alone versus continuous gemcitabine plus nab-paclitaxel aft… DOI 10.1016/s2468-1253(24)00197-3↗
8. Julia V. Mayerle · 4 shared papers, 2023–2024 · strength 0.60
   • Paper Changes over time in the course of advanced pancreatic cancer treatment with systemic chemotherapy: a pooled analysis o… DOI 10.1016/j.esmoop.2024.102944↗
   • Paper Three-month life expectancy as inclusion criterion for clinical trials in advanced pancreatic cancer: is it really a va… DOI 10.1007/s12094-023-03323-1↗
   • Paper Integrated Analysis of the RASH Study with the Use of the "Burden of Therapy" (BOTh®TM) Methodology-A Novel Tool for As… DOI 10.3390/curroncol30060436↗
9. Dirk Waldschmidt · 3 shared papers, 2024 · strength 0.52
   • Paper Gemcitabine and nab-paclitaxel combined with afatinib in metastatic pancreatic cancer - Results of a phase 1b clinical … DOI 10.1016/j.ejca.2024.113926↗
   • Paper Changes over time in the course of advanced pancreatic cancer treatment with systemic chemotherapy: a pooled analysis o… DOI 10.1016/j.esmoop.2024.102944↗
   • Paper Three-month life expectancy as inclusion criterion for clinical trials in advanced pancreatic cancer: is it really a va… DOI 10.1007/s12094-023-03323-1↗
10. Jens Thomas Siveke · 3 shared papers, 2023–2024 · strength 0.47
    • Paper Changes over time in the course of advanced pancreatic cancer treatment with systemic chemotherapy: a pooled analysis o… DOI 10.1016/j.esmoop.2024.102944↗
    • Paper Three-month life expectancy as inclusion criterion for clinical trials in advanced pancreatic cancer: is it really a va… DOI 10.1007/s12094-023-03323-1↗
    • Paper Integrated Analysis of the RASH Study with the Use of the "Burden of Therapy" (BOTh®TM) Methodology-A Novel Tool for As… DOI 10.3390/curroncol30060436↗
11. Steffen Ormanns · 3 shared papers, 2023 · strength 0.43
    • Paper Clinical Impact of Structured Post-Operative Surveillance in Resected Pancreatic Adenocarcinoma: Results from a Retrosp… DOI 10.1159/000528722↗
    • Paper Serum biomarker panel diagnostics in pancreatic ductal adenocarcinoma: the clinical utility of soluble interleukins, IF… DOI 10.1007/s00432-022-04112-z↗
    • Paper Precision Oncology in Pancreatic Cancer: Experiences and Challenges of the CCCMunich LMU Molecular Tumor Board. DOI 10.1007/s11523-023-00950-0↗
12. Stefan Holdenrieder · 2 shared papers, 2023–2026 · strength 0.41
    • Paper Distinct Mutation Signatures in Peripheral Blood Mitochondrial DNA from Liquid Biopsy Reveal Insights into Pancreatic C… DOI 10.3390/cells15060527↗
    • Paper Serum biomarker panel diagnostics in pancreatic ductal adenocarcinoma: the clinical utility of soluble interleukins, IF… DOI 10.1007/s00432-022-04112-z↗
13. Michael Ståhl · 2 shared papers, 2024 · strength 0.33
    • Paper Changes over time in the course of advanced pancreatic cancer treatment with systemic chemotherapy: a pooled analysis o… DOI 10.1016/j.esmoop.2024.102944↗
    • Paper Three-month life expectancy as inclusion criterion for clinical trials in advanced pancreatic cancer: is it really a va… DOI 10.1007/s12094-023-03323-1↗
14. Kathrin Heinrich · 2 shared papers, 2023–2024 · strength 0.32
    • Paper Gemcitabine and nab-paclitaxel combined with afatinib in metastatic pancreatic cancer - Results of a phase 1b clinical … DOI 10.1016/j.ejca.2024.113926↗
    • Paper Precision Oncology in Pancreatic Cancer: Experiences and Challenges of the CCCMunich LMU Molecular Tumor Board. DOI 10.1007/s11523-023-00950-0↗
15. Maximilian Reichert · 2 shared papers, 2024 · strength 0.31
    • Paper Alternating gemcitabine plus nab-paclitaxel and gemcitabine alone versus continuous gemcitabine plus nab-paclitaxel aft… DOI 10.1016/s2468-1253(24)00197-3↗
    • Paper Trametinib in combination with hydroxychloroquine or palbociclib in advanced metastatic pancreatic cancer: data from a … DOI 10.1007/s00432-024-05954-5↗
16. Frank Kullmann · 2 shared papers, 2023–2024 · strength 0.30
    • Paper Alternating gemcitabine plus nab-paclitaxel and gemcitabine alone versus continuous gemcitabine plus nab-paclitaxel aft… DOI 10.1016/s2468-1253(24)00197-3↗
    • Paper Integrated Analysis of the RASH Study with the Use of the "Burden of Therapy" (BOTh®TM) Methodology-A Novel Tool for As… DOI 10.3390/curroncol30060436↗
17. Volker Kunzmann · 2 shared papers, 2023–2024 · strength 0.30
    • Paper Alternating gemcitabine plus nab-paclitaxel and gemcitabine alone versus continuous gemcitabine plus nab-paclitaxel aft… DOI 10.1016/s2468-1253(24)00197-3↗
    • Paper Integrated Analysis of the RASH Study with the Use of the "Burden of Therapy" (BOTh®TM) Methodology-A Novel Tool for As… DOI 10.3390/curroncol30060436↗
18. Thomas Jens Ettrich · 2 shared papers, 2023–2024 · strength 0.30
    • Paper Alternating gemcitabine plus nab-paclitaxel and gemcitabine alone versus continuous gemcitabine plus nab-paclitaxel aft… DOI 10.1016/s2468-1253(24)00197-3↗
    • Paper Integrated Analysis of the RASH Study with the Use of the "Burden of Therapy" (BOTh®TM) Methodology-A Novel Tool for As… DOI 10.3390/curroncol30060436↗
19. Stephan Krüger · 2 shared papers, 2023 · strength 0.30
    • Paper Clinical Impact of Structured Post-Operative Surveillance in Resected Pancreatic Adenocarcinoma: Results from a Retrosp… DOI 10.1159/000528722↗
    • Paper Serum biomarker panel diagnostics in pancreatic ductal adenocarcinoma: the clinical utility of soluble interleukins, IF… DOI 10.1007/s00432-022-04112-z↗
20. Jens Werner · 2 shared papers, 2023 · strength 0.29
    • Paper Clinical Impact of Structured Post-Operative Surveillance in Resected Pancreatic Adenocarcinoma: Results from a Retrosp… DOI 10.1159/000528722↗
    • Paper Precision Oncology in Pancreatic Cancer: Experiences and Challenges of the CCCMunich LMU Molecular Tumor Board. DOI 10.1007/s11523-023-00950-0↗
21. Georg Beyer · 2 shared papers, 2023–2024 · strength 0.28
    • Paper Trametinib in combination with hydroxychloroquine or palbociclib in advanced metastatic pancreatic cancer: data from a … DOI 10.1007/s00432-024-05954-5↗
    • Paper Precision Oncology in Pancreatic Cancer: Experiences and Challenges of the CCCMunich LMU Molecular Tumor Board. DOI 10.1007/s11523-023-00950-0↗
22. Hannah Randeu · 1 shared paper, 2026 · strength 0.26
    • Paper Distinct Mutation Signatures in Peripheral Blood Mitochondrial DNA from Liquid Biopsy Reveal Insights into Pancreatic C… DOI 10.3390/cells15060527↗
23. Sebastian Kobold · 1 shared paper, 2022 · strength 0.20
    • Paper Novel systemic treatment approaches for metastatic pancreatic cancer. DOI 10.1080/13543784.2022.2037552↗
24. Victoria Probst · 1 shared paper, 2024 · strength 0.18
    • Paper Gemcitabine and nab-paclitaxel combined with afatinib in metastatic pancreatic cancer - Results of a phase 1b clinical … DOI 10.1016/j.ejca.2024.113926↗
25. Michael Quante · 1 shared paper, 2024 · strength 0.18
    • Paper Gemcitabine and nab-paclitaxel combined with afatinib in metastatic pancreatic cancer - Results of a phase 1b clinical … DOI 10.1016/j.ejca.2024.113926↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.